Onda (Ondansetron)

Ondansetron, the active ingredient in Onda, is a 5‑HT3 receptor antagonist presented as a 4 mg oral tablet for oral use. It helps prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Onda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Onda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: helps control nausea during and after radiotherapy. - Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures. - Pregnancy‑related hyperemesis gravidarum (off‑label): may be used when conventional therapy fails, under specialist supervision.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement difficulty. - Diarrhoea: loose stools, usually transient. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - QT prolongation: potential cardiac rhythm disturbance. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Serotonin syndrome: agitation, tremor, hyperreflexia when combined with serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances.

When prescribing Ondansetron, clinicians should consider several safety aspects.

- Cardiac monitoring: assess baseline ECG in patients with known cardiac risk. - Electrolyte balance: correct hypokalaemia or hypomagnesemia before use. - Concomitant serotonergic drugs: avoid or monitor for serotonin syndrome. - Pregnancy: use only if benefit outweighs risk; discuss with obstetrician. - Breastfeeding: evaluate risk‑benefit; limited data available. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Ondansetron may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Apomatinib (  ).   g   g  

-   g   t  .

Moderate   g   ewline  .

-   -  . -  t  . -  . -  . -  . -  . -  . -  . -  . -  . -  . -  . -  -  g  t  t . -  g  g. -  -  t. -  g. -  g. -  g. -  -  g. -  -  g. -  -  g. -  -  -  g. -  -  g. -  -  -  g -  -  g -  -  -  g -  -  t. -  g");